Pioneering Treatments for Erectile Dysfunction and Overactive Bladder
The work done by investigators with the Department of Urology at Montefiore has served as the basis for significant clinical trials. Research on the role of potassium channels in urogenital smooth muscle function led to the development of a gene therapy treatment for erectile dysfunction and overactive bladder. Clinical Phase I trials have been conducted for both these conditions and represent the only gene therapy treatment for a benign urological condition ever approved by the FDA for clinical investigation work.
These clinical trials are ongoing and were featured on the cover of Human Gene Therapy journal.
In addition, media outlets such as the BBC, Discover Magazine, The Sunday Times (UK), U.S News & World Report, Marie Claire, The New York Daily News, UPI and Fox News have covered our Department’s involvement in a study that used an innovative new drug-delivery system—nanoparticles infused with nitric oxide and applied topically—to successfully treat erectile dysfunction in animals. Current erectile dysfunction drugs are taken orally and can cause troubling side effects, which could be minimized by topical application directly to the affected area.
Joel M. Friedman, M.D., Ph.D., professor of physiology & biophysics and of medicine at Albert Einstein College of Medicine and his son, Adam Friedman, M.D., Director of Dermatologic Research at the Unified Division of Dermatology at Einstein, developed the nanoparticle technology.
Kelvin Davies, Professor, Department of Urology and Professor, Department of Physiology & Biophysics acted as Principal Investigator and Senior Author on the two papers published on applying this technology. The expectation is that we will have a clinical application in the next few years; a development could help millions of men every year.